Stephens Inc. AR Reduces Stock Position in Solventum Co. (NYSE:SOLV)

Stephens Inc. AR decreased its stake in shares of Solventum Co. (NYSE:SOLV) by 34.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,449 shares of the company’s stock after selling 1,773 shares during the period. Stephens Inc. AR’s holdings in Solventum were worth $228,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in SOLV. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Solventum by 2.0% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,677 shares of the company’s stock worth $904,000 after buying an additional 264 shares in the last quarter. Strategic Financial Concepts LLC bought a new position in Solventum in the 4th quarter valued at $990,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Solventum by 55.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,791 shares of the company’s stock valued at $3,959,000 after purchasing an additional 21,362 shares in the last quarter. abrdn plc grew its position in shares of Solventum by 0.5% during the 4th quarter. abrdn plc now owns 183,530 shares of the company’s stock valued at $12,120,000 after purchasing an additional 834 shares in the last quarter. Finally, Spire Wealth Management bought a new position in shares of Solventum in the fourth quarter worth $37,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SOLV shares. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus price target of $68.29.

Solventum Trading Down 0.4 %

NYSE:SOLV opened at $74.04 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a 50 day moving average of $70.75 and a 200 day moving average of $68.58.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.